Pharmacy

Your Article Summary

See Latest Articles

CRESTOR reduced risk of cardiovascular events in elderly patients in new analysis of JUPITER
AstraZeneca, 09/01/09

A new analysis from the JUPITER study showed that CRESTOR 20mg reduced the composite primary end point of major cardiovascular events by 39%, compared to placebo, in elderly patients with LDL–C less than 130 mg/dL and elevated high–sensitivity C–reactive protein. This analysis was conducted in 5,695 patients aged 70 years or older. The results from this analysis are consistent with the CV risk reduction seen across all patients taking rosuvastatin in the primary JUPITER analysis.

Today in Cardiac/Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09

Beta-Adrenergic Antagonists in Hypertension: A Review of the Evidence
Annals of Pharmacotherapy, 11/25/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

 See all of Cardiac/Hypertension

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

A Multicenter, Double-Blind, Randomized, Parallel Group Study Comparing Polyvinyl Chloride and Polyvinyl Chloride-Free Catheter Materials
The Journal of Urology, 11/24/09

Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Research, 11/16/09

Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkins Lymphoma
Cephalon, 11/06/09

 See all of Major Studies